India, Oct. 30 -- Pelthos Therapeutics, Inc. (PTHS) announced a definitive agreement to merge with Castle Creek Biosciences, creating a biotechnology company focused on developing treatments for serious skin diseases. Following the transaction, the combined company will continue operating as Pelthos Therapeutics and remain listed on the NYSE American under the ticker symbol PTHS.
The combination brings together Pelthos' commercial dermatology portfolio and Castle Creek's late-stage fibroblast-based cell and gene therapy platform, expanding the company's capabilities across multiple therapeutic modalities.
Castle Creek's lead candidate, D-Fi (dabocemagene autoficel; FCX-007), is an investigational, injectable, gene-modified cell therapy be...